Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial

Mayo Clinic Proceedings

Volumn 81, Issue 1, 2006, Pages 17-27

  Bogan, Richard K ^a   Fry, June M ^b   Schmidt, Markus H ^c   Carson, Stanley W ^d   Ritchie, Sally Y ^e  

^a SleepMed of South Carolina   (United States)

^b Center for Sleep Medicine   (United States)

^c Ohio Sleep Medicine and Neuroscience Institute   (Ireland)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PLACEBO; ROPINIROLE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROSIS; HALLUCINATION; HEADACHE; HUMAN; INTERNATIONAL RESTLESS LEGS SCALE; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; THORAX PAIN; TRAFFIC ACCIDENT; UNITED STATES; VOMITING;

EID: 30144433526     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.1.17     Document Type: Article

References (39)

1. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med. 2000;160:2137-2141.
2. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord. 2001;16:1159-1163.
3. Ulfberg J, Nystrom B, Carter N, Edling C. Restless legs syndrome among working-aged women. Eur Neurol. 2001;46:17-19.
4. Tan EK, Ondo W. Restless legs syndrome: clinical features and treatment. Am J Med Sci. 2000;319:397-403.
5. Walters AS, International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634-642.
6. Allen RP, Picchietti D, Hening W, Trenkwalder C, Walters AS, Montplaisir J, International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119.
7. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61-65.
8. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemiology, Symptoms, and Treatment) primary care study. Sleep Med. 2004;5:237-246.
9. Washburn T, Allen R, Abetz L, Kirsch J, Barley C. Sleep and cognitive functioning in people with restless legs syndrome (RLS): comparisons with a normative population [abstract]. Sleep. 2003;26(suppl):A331. Abstract 0832.N.
10. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004;26:925-935.
11. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 1999;52:932-937.
12. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology. 2000;54:502-504.
13. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304-309.
14. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004; 62:1563-1567.
15. Winkelmann J, Schadrack J, Wetter TC, Zieglgansberger W, Trenkwalder C. Opioid and dopamine antagonist drug challenges in untreated restless legs syndrome patients. Sleep Med. 2001;2:57-61.
16. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry. 2002;35:109-111.
17. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind; controlled study. Neurology. 1988;38:1845-1848.
18. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep. 1993;16:717-723.
19. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995;18:681-688.
20. Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep. 1999;22:1073-1081.
21. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology. 1999;52:285-290.
22. Saletu M, Anderer P, Hogl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm. 2003;110:611-626.
23. Trenkwalder C, Collado Seidel V, Kazenwadel J, et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord. 2003;18:1184-1189.
24. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205-213.
25. Littner M, Kushida C, Anderson WM, et al, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27:557-559.
26. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH, Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27:560-583.
27. Silber MH, Ehrenberg BL, Allen RP, et al, Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79:916-922.
28. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27:907-914.
29. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Therapy with Ropiunirole Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92-97.
30. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K, TREAT RLS 2 Study Group. Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414-1423.
31. Karrasch J, Haan J, Kruger AJ, Vole D, Montplaisir J. Maintained efficacy with ropinirole: results of a multinational 36-week study of patients with RLS [abstract]. Sleep. 2004;27(suppl):A294. Abstract 658.
32. Garcia-Borreguero D, Lee D, Ball E. Ropinirole is well tolerated and effective for the long-term treatment of RLS [abstract]. Neurology. 2005; 64(suppl 1):A42. Abstract P01.046.
33. Walters AS, LeBrocq C, Dhar A, et al, International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121-132.
34. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Dept of Health, Education, and Welfare; 1976:217-222. Publication No. ADM 76-338.
35. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259.
36. Zigmond A, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
37. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41-44.
38. Nyenhuis DL, Yamamoto C, Luchetta T, Terrien A, Parmentier A. Adult and geriatric normative data and validation of the profile of mood states. J Clin Psychol. 1999;55:79-86.
39. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286-1292.